SCHEMBL8968285

SCHEMBL8968285

C=C(F)c1ccc(N2CCN[C@H](c3ccccc3)C2)nc1C(=O)c1cccnc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 12/20 0.49
RPS6KB1 P23443 1/20 0.43
PRKCD Q05655 7/20 0.40
PRKCA P17252 6/20 0.39
ALDH1A1 P00352 2/20 0.39
GSK3B P49841 2/20 0.38
PRKCB P05771 1/20 0.37
FLT3 P36888 1/20 0.37
PRKCE Q02156 1/20 0.37
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE10A Q9Y233 1/20 0.36
LMNA P02545 1/20 0.35
NAPEPLD Q6IQ20 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8968114 1.00 PRKCQ (0.49) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8968269 1.00 PRKCQ (0.49) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8968518 0.96 PRKCQ (0.47) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8968932 0.93 PRKCQ (0.42) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8968254 0.90 GSK3B (0.43) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8967927 0.85 PRKCQ (0.48) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8967368 0.85 PRKCQ (0.48) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8967937 0.85 PRKCQ (0.48) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8967908 0.85 PRKCQ (0.48) PRKCQRPS6KB1PRKCDPRKCAALDH1A1
SCHEMBL8966823 0.85 PRKCQ (0.48) PRKCQRPS6KB1PRKCDPRKCAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 PRKCQ 38/4885RPS6KB1 401/4885PRKCD 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.